Journal Reviews

Allergy journal cover image.

Biologicals for severe chronic rhinosinusitis with nasal polyps. Any use?

5 November 2021 | | ENTA-Rhinology / Sinus | chronic rhinosinusitis, dupilumab, mepolizumab, omalizumab, reslizumab

Recent advances and knowledge of inflammatory endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP) led to introduction of biological agents such as monoclonal antibodies targeting IgE (omalizumab) and Interleukins (ILs) such as IL4R alpha (dupilumab) and IL5. The European Academy...

ALLERGY cover

CRSwNP, another monoclonal antibody

1 July 2019 | | ENTA-Rhinology / Sinus | biomarkers, dupilumab, nasal polyposis, nasal secretions, type 2 inflammation

Interleukins 4, 5 and 13 were shown to be important factors in type 2 inflammation, which characterises chronic rhinosinusitis with nasal polyposis (CRSwNP). In CRSwNP non-responders and those who recur short after-surgery monoclonal antibodies might be an answer. Examples include...